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ABSTRACT
T
he success of genome-wide association studies relies
on much of the risk of common diseases being due to
common genetic variants; but evidence for this is
inconclusive. The results of published genome-wide
association studies are examined to see what can be learnt
about the distribution of disease-associated variants and how
this might inﬂuence future study design. Although replicated
disease-associated variants tend to be very common and
frequency is inversely correlated with estimated effect size,
our simulations suggest that such observations are the result
of power. We ﬁnd that for studies conducted to date, the
frequency and effect size of signiﬁcantly associated alleles are
likely to be similar to those of the underlying disease alleles
that they represent. Little of the genetic variation of disease
has been explained so far, but current studies are only
adequately powered to detect very common alleles unless
they greatly increase disease risk. Thus, although the truth of
the common disease / common variant hypothesis remains
undecided, recent successes suggest that there are many more
common genetic disease-associated variants, requiring larger
studies to be identiﬁed.
Introduction
In the last year there has been a dramatic increase in the
publication of the results of genome-wide association (GWA)
studies. The timing reﬂects recent technological
improvements in genotyping technology, but the impetus
behind these studies can be traced back to two key papers
from 1996 [1,2]. These two papers argued that common
variants may underlie many common diseases, that these
would be more easily found using population-based
association studies rather than family-based linkage analysis
even if this required testing every gene in the genome [1], and
that all common variants in human genes should be identiﬁed
[2]. These proposals gained credence and led to the
International HapMap Project [3], with the aim of
cataloguing common human genetic variants. Combined with
the latest SNP chip genotyping technologies allowing the
simultaneous genotyping of hundreds of thousands of
markers, HapMap has enabled GWA studies to be conducted,
leading to the recent discovery of common genetic variants
associated with diseases such as coronary heart disease [4–8],
breast cancer [9–11] and type II diabetes [12–18].
GWA studies require the collection of large numbers of
cases with a particular disease and controls, genotyped at
many markers across the genome. As a result of the
association (linkage disequilibrium, or LD) between alleles at
nearby loci, not all loci in a region need be typed for the
majority of common variation to be captured. Marker
(usually single nucleotide polymorphism or SNP) spacing
should be dense enough to capture the variation at those loci
that have not been genotyped. SNPs may be chosen randomly
across the genome or may be chosen speciﬁcally for their
coverage (using a pilot sample or existing data such as
HapMap) in which case they are known as tagging SNPs [19].
Studies should be designed in terms of both sample size and
marker coverage to have sufﬁcient power to detect common
disease susceptibility alleles of modest effect. Genotype data
may be analysed in various ways, but the simplest is a
comparison of frequencies between cases and controls, often
using the Cochrane-Armitage trend test, which assumes a
multiplicative risk model. Power issues will be discussed in
more depth later.
GWA represents a method for capturing a new class of
disease-associated genetic variants. Pedigree-based
association studies utilise families in which disease clusters,
and so are powered to ﬁnd rare variants of large effect. GWA
meanwhile relies on population-based samples, and so
requires common variants (as rarer variants will be
unobserved) of more modest effect, which could not be found
using traditional linkage-based approaches.
Common disease/common variant hypothesis. The
common disease / common variant (CDCV) hypothesis
assumes that much of the genetic variation of a common
complex disease is due to relatively few common variants. If
multiple rare genetic variants were the primary cause of
common complex disease, association studies would have
little power to detect them; particularly if allelic
heterogeneity existed. Ironically, given the recent huge
ﬁnancial and scientiﬁc investment in GWA, there is not a
great deal of evidence in support of the CDCV hypothesis and
much of it is equivocal. The ﬁrst evidence was that common
genetic variants had been found to increase the risk of some
common diseases, such as APOE which increases risk for
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convincingly replicated [21]. But there also exist examples of
rare variants inﬂuencing common disease [22,23], telling us
that both rare and common variants may inﬂuence common
diseases, although we do not know which is more important.
The second source of evidence came several years later from
theoretical population genetic models. Unfortunately, any
conclusions depend greatly on the model used, for which
many of the variables are unknown or at least difﬁcult to
estimate [24–27].
Despite such limited and sometimes contradictory
evidence supporting the CDCV hypothesis, GWA studies have
proved very popular. Their success at uncovering many
common alleles associated with common disease suggests that
the hypothesis is true to an extent, at least for some diseases
studied, but it is useful to look at the results in more depth.
GWA studies are said to represent an ‘‘agnostic’’ [28]
approach to identifying the genetic variants that inﬂuence
common human diseases, being ‘‘unbiased by prior
assumptions about the DNA alterations responsible’’ [29].
Thus, the results of published GWA studies may include
valuable information about the genetic basis of common
diseases, especially the CDCV hypothesis, as in [21]. The more
that is known about the underlying genetic basis of human
disease the better studies can be designed to identify those
genetic variants that inﬂuence human diseases.
The simplest approach is to examine the distribution of the
frequency of those disease-associated alleles found by GWA
studies and subsequently conﬁrmed. But this does not
account for rarer variants being harder to detect or disease-
associated alleles having different frequencies from the
causative alleles they tag. For this reason, we simulated data to
see what underlying distributions could give rise to the
observed frequency distribution of signiﬁcantly associated
alleles. These simulations were used to estimate correlations
between factors such as marker frequency and effect size, and
the frequencies of the most signiﬁcant marker allele and the
disease allele.
Proportion of genetic risk
While disease-susceptibility variants found using pedigree-
based linkage analysis tend to have large relative risks, they
have little effect on disease risk at a population level, due to
their rarity. More common genetic variants, despite having
only moderate disease risk, may be far more important in
terms of public health simply because they are more common.
Many GWA reports have included estimates of the inﬂuence
of the genetic variants found on population-level disease risk,
using various methods. We discuss how the methods vary and
how these estimates may be interpreted, as the proportion of
risk explained may inﬂuence future study design.
Findings from genome-wide analyses. The results of 54
studies across 22 different diseases (Table S1) were examined.
Most were GWA analyses, while some followed up the results
of GWA analyses. Only those SNPs found initially in a GWA
study (excluding the few SNPs that were already known, such
as those in the Major Histocompatibility Complex) and that
reached nominal signiﬁcance in at least one other study were
included. This gave 45 disease-associated SNPs. Almost all had
reached genome-wide signiﬁcance (p , 5310
 7 as in [6]) and
been replicated in at least one independent population. Two
SNPs did not reach this level of signiﬁcance in a single study
but had a p-value of at least 10
 5 in two independent studies.
The estimated allele frequency and odds ratio (OR)
(preferably from follow-ups to reduce bias) were recorded for
each conﬁrmed disease-associated SNP. In summarizing the
data, SNPs associated with age-related macular degeneration
[30] and Exfoliation Glaucoma [31] were ignored, as their
estimated odds ratios are very high and they were detected
with small sample sizes, making them both outliers that tend
to skew the results from the remaining 43 SNPs.
The distribution of disease-associated allele frequencies
(Figure 1A) looks reasonably Normal, despite the small
number of observations, with a median frequency of 0.40
(95% CI: 0.37, 0.48) and a mean of 0.43 (95% CI: 0.39, 0.49).
Only three of the 43 SNPs have minor allele frequency (MAF)
,0.1 (Figure 1B). This suggests that most of the alleles
associated with common diseases are common. The
distribution of estimated ORs (Figure 1C) is skewed with a
median of 1.25 (95% CI: 1.2, 1.29). Only eight of the 43 SNPs
have an OR .1.5 and only one of these an OR .2.
Superﬁcially, these results suggest that most disease-
associated alleles are fairly common, but this does not
account for power. Susceptibility alleles where the MAF is
high are far more easily detected.
Pearson’s correlation between susceptibility allele
frequency and OR was  0.28 (95% CI:  0.53,0.07, p ¼ 0.07)
(Figure 1D). A negative correlation between effect size and
frequency may be expected due to selection pressures [27].
However, the stronger negative correlation when MAF is
studied instead of susceptibility allele frequency ( 0.48: 95%
CI:  0.66,  0.19, p ¼ 0.001) suggests that some of this
correlation is due to power. As allele frequency tends towards
the extremes (0 and 1), power will decrease so only large
effects will be found. There is no need to invoke selection to
explain this observation.
Thus, apparent patterns in the ﬁndings may be explained
by power considerations. We investigated these potential
problems by simulation.
Simulation of genome-wide analyses. Realistic case/control
data were simulated utilising the ENCODE data (http://www.
hapmap.org) assuming a single ungenotyped disease
susceptibility locus, based on realistic frequency distributions
[26,32] (Figure S1) with mutation rates chosen to give disease
alleles that were either almost exclusively low frequency (bS¼
0.1), mostly low frequency but some more frequent (bS¼1), or
mainly higher frequency (bS ¼ 3) (Figure S2). n ¼ 1,000 or n ¼
3,000 cases and controls were produced with genotype
relative risks (GRRs) of 1.2, 1.5, and 2. Genotyped SNPs were
selected to mimic those on a SNP chip. The Cochrane-
Armitage trend test was applied to all ‘‘genotyped’’ SNPs and
the p-value for genome-wide signiﬁcance set at a ¼ 5 3 10
 7
[6]. See Text S1 for more details of simulations. Ideally, we
would hope that the distributions of signiﬁcant marker locus
frequencies are distinguishable at different mutation rates.
The different distributions are easily discernable when
GRR ¼ 2 (Figures 2 and 3), even for n ¼ 1,000 (Figure 2).
However, when the GRR ¼ 1.5, the distributions are quite
similar for n¼1,000 (Figure 2). Only when n¼3,000 is there a
clear increase in rare variants for bS ¼ 0.1 or 1 (Figure 3).
When GRR¼1.2 (close to the median of the observed GRRs in
GWA studies), the distributions for bS ¼ 0.1, 1, and 3 are
extremely similar for both n ¼ 1,000 and 3,000.
Thus, whatever the underlying distribution of disease
PLoS Genetics | www.plosgenetics.org February 2008 | Volume 4 | Issue 2 | e33 0002variant frequencies, the results suggest that unless the effect
size or sample size is large (GRR . 1.5 or n ¼ 3,000),
simulations with mostly rare (bS ¼ 0.1) or common (bS ¼ 3)
susceptibility alleles produce similar distributions of disease-
associated allele frequencies that look Normal and not too
skewed, with a median of 0.2–0.4. These results seem to hold
for modes of inheritance other than multiplicative (Text S2,
Figures S3–S7).
The correlation between GRR and MAF ranged from 0.33
to  0.51—a negative correlation between GRR and allele
frequency of similar magnitude to that of the real data,
though none was simulated.
For n ¼ 1,000 and GRR ¼ 1.2, 1.5, and 2, correlations
between marker and susceptibility allele frequency were 0.63,
0.92, and 0.83, respectively. For n ¼ 3,000, correlations for
GRR ¼ 1.2, 1.5, and 2, were 0.91, 0.85, and 0.62, respectively.
doi:10.1371/journal.pgen.0040033.g001
Figure 1. Allele Frequencies and ORs Observed in GWA Studies
(A and B) Histograms of susceptibility allele frequency and MAF, respectively, at confirmed susceptibility loci.
(C) Histogram of estimated ORs at confirmed susceptibility loci.
(D) Plot of estimated OR against susceptibility allele frequency at confirmed susceptibility loci. ‘‘I’’s represent SNPs associated with autoimmune disease,
‘‘C’’s represent SNPs associated with cancer, and small circles represent SNPs associated with other diseases.
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correlation is strong. The frequency of the disease-associated
allele at the marker locus is thus a good indicator of the
frequency of the genuine disease allele at the susceptibility
locus under the model used here.
The absolute difference between estimated GRR and the
true, simulated GRR was examined. The average difference
for GRR¼1.2, 1.5, 2 was 0.31, 0.14, 0.19 for n¼1,000 and 0.08,
0.08, 0.32 for n ¼ 3,000. Thus, GRR estimates are likely to be
fairly reliable. It is interesting that estimates of both disease
allele frequency and GRR are generally less reliable as power
increases (either through greater sample size or GRR). This is
likely to be because when power is high, markers that are in
weaker LD with the causative locus may reach signiﬁcance
and estimates will then be less reliable. This is reﬂected in the
fact that GRR estimates tend to overestimate for n¼1,000 but
less so for n ¼ 3,000. When n is larger, power is greater and
SNPs in weaker LD reach signiﬁcance, but their weak LD will
result in lower GRR estimates. Smaller sample sizes exhibit
the so-called ‘‘winner’s curse’’, consistently overestimating
effect sizes [33,34].
We also found that even when the true disease model was
dominant/recessive, the best-ﬁtting model at the marker locus
was biased slightly but consistently away from dominant/
recessive towards a multiplicative risk model (Text S2). This
suggests that even when the true mode of inheritance is
doi:10.1371/journal.pgen.0040033.g002
Figure 2. Simulations Showing Frequencies of Disease-Susceptibility–Related Loci Found with p , 5 3 10
 7 and a Sample Size of 1,000
Rows are (from top to bottom) GRR ¼ 1.2, 1.5, 2; columns are (from left to right) bS ¼ 0.1, 1, 3.
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inheritance at the most signiﬁcant marker locus is biased
towards multiplicative. These results also provide further
support for using a test, such as the Cochrane-Armitage trend
test, that assumes a multiplicative risk model.
Our models assume a single disease variant in each region.
If there are multiple disease variants, the results may be
somewhat different. Nor have we considered very rare
causative alleles. It would be hoped that such effects would
not greatly affect the conclusions.
Power considerations. These results suggest that the
distribution of frequencies for conﬁrmed disease-associated
alleles is far more reﬂective of power than of the underlying
distribution of disease alleles. Given that the case/control
samples for GWA usually number in the thousands and are
gradually increasing, it might be expected that such studies
are well-powered. However, several papers have shown that,
given the strict genome-wide signiﬁcance criteria that studies
must fulﬁll, power is much less than might be imagined
[35,36].
Power estimates produced in Quanto [37,38], assuming all
variants have been typed with a multiplicative mode of
inheritance, show that there is good power to detect a variant
with a GRR of 2 even at low frequency (Figure 4). A variant
doi:10.1371/journal.pgen.0040033.g003
Figure 3. Simulations Showing Frequencies of Disease-Susceptibility–Related Loci Found with p , 5 3 10
 7 and a Sample Size of 3,000
Rows are (from top to bottom) GRR ¼ 1.2, 1.5, 2; columns are (from left to right) bS ¼ 0.1, 1, 3.
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3,000, but only has decent power for MAF . 0.2 for n¼1,000.
For GRR ¼ 1.3, power is good at high frequency (MAF . 0.2)
for n¼3,000, but generally poor (power , 0.2) whatever MAF
for n¼1,000. For GRR¼1.2, power is poor even for n¼3,000.
These power calculations may seem dispiriting, given that the
median observed GRR is about 1.2. In fact, these results are
optimistic. The calculations assume that the disease locus
itself has been genotyped, when in fact it is more likely to be a
nearby SNP in incomplete LD. Given problems of overﬁtting,
incomplete marker ascertainment [39], population
differences, SNP failure (6.2% in [6]), and uneven spacing,
there are many sources causing overestimation of coverage. If
there are multiple susceptibility variants interacting
epistatically (so that their marginal effects are weak) power
will be further reduced.
The effect of coverage (measured by r
2) on power is best
understood by knowing that to detect an ungenotyped
variant using a genotyped SNP, the sample size must be
increased by a factor of 1/r
2 compared to the sample size
required when testing the variant itself [40]. A disease locus
whose effect is detectable when genotyped with a sample of n
¼ 1,000 will require n ¼ 1,250 if a nearby SNP is instead
genotyped with an r
2 ¼ 0.8 between the two. Power estimates
from our simulations bear these results out and show the
effect of using tagging SNPs (Figure S2).
Reports of coverage are often reported as the proportion
of known SNPs captured by typed markers with r
2 . 0.8.
While a useful shorthand for comparison, it is a gross
simpliﬁcation—disease SNPs captured with r
2 , 0.8 may still
be captured, but with less power. It should be remembered
that choosing 0.8 as the cutoff for coverage is quite arbitrary,
as is using p ¼ 0.05 as a cutoff for signiﬁcance in hypothesis
testing.
Despite low power, disease-associated SNPs have been
found. The power distribution also suggests that those
variants that have been found are the most common and so
the easiest to detect. Few associated variants have a frequency
below 0.2, but the limited power at these frequencies for
GRRs , 1.5 suggests that they may represent only a fraction
of the existing disease variants. Estimating how much of the
overall risk known variants explain may be useful.
Estimating the risk explained. Another way of looking at
risk is to estimate how much of the (genetic) risk is explained
by known genetic variants. Some studies claim their ﬁndings
explain much of the variation in disease risk, but the methods
used differ and the ﬁndings are variable. Population
attributable risk (PAR) estimates the effect of a factor on
incidence: if that factor were removed from the population,
by how much would incidence fall? Other measures estimate
the proportion of genetic variance or excess familial risk
explained by a variant, a more direct measure of the known
proportion of overall genetic risk. If a susceptibility allele is
very common in the population, say with a frequency close to
1, it is likely to have an important effect on disease risk and
will have a high PAR, even if its effect on risk is small, because
in its absence general disease risk will fall. However, it will
make very little contribution to variation in disease risk
whatever its effect size because it is so common.
Reported PARs tend to be high, as the variants are
common: 0.54 for Restless Legs Syndrome [41], 0.38 for
Coronary Artery Disease [7], and 0.13 for Prostate Cancer
[42]; while measures of the proportion of the genetic risk are
lower: excess familial risk of 0.036 for Breast Cancer [11] and
0.002 of the variance in risk for Multiple Sclerosis [43].
Tellingly, estimates of PAR for the replicated SNP found for
colorectal cancer vary between 0.11 and 0.42 (because of
differences in frequency between populations), while
explaining only 0.009–0.018 of the increased risk to siblings of
cases [44]. It is also well known that initial estimates are likely
doi:10.1371/journal.pgen.0040033.g004
Figure 4. Power Calculated Using Quanto for 1,000 Cases and Controls (A) and 3,000 Cases and Controls (B)
Lines are for GRR ¼ 2 (solid), 1.5 (dashed), 1.3 (dotted), 1.2 (dashed and dotted). A multiplicative mode of inheritance is assumed.
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as Parkinsons disease [46], bipolar disorder [6,47], and
hypertension [6], no new replicable variant has yet been
found using GWA.
Misunderstanding PAR may give the impression that for
several reported diseases, most of the underlying genetic
cause has been identiﬁed. In fact, the variants found to date
are likely to represent only a small proportion of the overall
variation in disease risk [29]. It is likely that there are other
common variants to be found (if the CDCV hypothesis is
true), and that many rare variants also have an effect [48] but
will be far more difﬁcult to detect.
Discussion
It may be convenient to assume that the genetic variants
underlying common diseases are themselves common, simply
because that is what has been observed to date. However, our
results show that such an assumption would be naı ¨ve and
potentially misleading.
Through simulation of common disease, we have shown
that for the size of studies carried out so far and the effect size
of the variants found, we would expect any signiﬁcantly
associated alleles to be common even when the causative
genetic variants are mostly rare. For n ¼ 1,000, this result
changes only if the effect size is large (GRR¼2) (Figure 2), and
even for n ¼ 3,000 the frequency distributions of signiﬁcant
alleles are very similar for rare and common causative genetic
variants unless the effect size is quite large (GRR¼1.5) (Figure
3). At the smallest effect size (GRR ¼ 1.2, the closest to the
median observed in reality), there is little to distinguish
distributions even at sample sizes of 3,000 cases and controls
(Figure 3).
Simulations show a strong correlation between the
frequency of the disease-associated allele and the causative
allele. Thus, common marker variants associated with disease
represent similarly common variants directly causing disease,
demonstrating that common variants certainly exist.
Estimates of the genetic variation explained suggest that
even for those diseases where common genetic variants have
been found, most genetic variation is still to be uncovered.
This does not imply that the CDCV hypothesis is necessarily
false, rather that power is low for current study size unless
MAF is high or effect size is large. Thus, while many very
frequent disease variants have been found for the diseases
studied so far by GWA, there may be many more variants that
are of moderate frequency but that current studies are not
large enough to ﬁnd. We cannot yet rule out the possibility
that much genetic variation is due to rare variants.
And what of the future? Sample sizes will increase, leading
to greater power to ﬁnd rare variants. But when samples are
larger, increased power may mean that markers in weaker LD
with the disease locus reach signiﬁcance, if the same (or less
stringent, if Bayesian) signiﬁcance levels are used. Thus, as
sample sizes increase, rare variants are more easily detected,
but the most signiﬁcantly associated individual markers may
not be rare themselves. Sequencing is the only way to
completely avoid this latter problem, although it only slightly
improves power (Figure S2) and will not on its own remove
the bias towards ﬁnding more common variants. There is
likely to be a limit to how large population-based studies can
get, and so there may be a further class of variants that are
too rare to be captured by GWA but are not sufﬁciently high
risk to be captured by population-based linkage (for examples
see [49]). New approaches will be needed to ﬁnd these,
perhaps utilising bioinformatics-based methods to identify
candidate genes and variants.
Many of the ﬁndings from GWA studies that have not quite
reached genome-wide signiﬁcance may be genuine and could
be uncovered by combining the results from several studies,
perhaps by meta-analysis or marker imputation if SNP panels
vary [50].
For now, it is unlikely that much can be inferred about the
CDCV hypothesis from the results of GWA studies. The
successes in ﬁnding common variants associated with
common diseases are encouraging, but, as our ﬁndings show,
we cannot yet be sure whether the common disease-
associated variants found so far represent the tip of the
iceberg or the bottom of the barrel.
Supporting Information
Figure S1. Distribution Function of Frequencies According to
Wright’s Formula When r ¼ 12, bN ¼ 0.01 and bS ¼ 0.1, 1, or 3
(Notation from Pritchard, 2001)
Used for simulated disease allele frequency distribution, assuming
that all disease alleles are at a single locus.
Found at doi:10.1371/journal.pgen.0040033.sg001 (439 KB TIF).
Figure S2. Estimated Power
Power estimated by simulation to reach signiﬁcance level of p ¼ 5 3
10
 7, grouped by frequency 0.05–0.1, 0.1–0.15, ..., 0.45–0.5 for sample
sizes n¼1,000 and 3,000 (ﬁrst and second row, respectively) and GRR
¼1.2, 1.5, 2 (ﬁrst, second, and third column, respectively). Circles are
for Affymetrix-like coverage, crosses are for sequencing all variants
with MAF . 0.05.
Found at doi:10.1371/journal.pgen.0040033.sg002 (2.2 MB TIF).
Figure S3. Simulations Showing Frequencies of Disease-
Susceptibility-Related Loci Found with p , 5 3 10
 7 and a Sample
Size of 1,000 Under a Recessive Disease Model
GRRs are chosen such that the population prevalence is equivalent to
GRRs under a multiplicative model of GRR ¼ 1.2, 1.5, 2. Rows are
(from top to bottom), GRR ¼ 1.2, 1.5, 2; columns are (from left to
right) bS ¼0.1, 1, 3.
Found at doi:10.1371/journal.pgen.0040033.sg003 (1.8 MB TIF).
Figure S4. Simulations Showing Frequencies of Disease-
Susceptibility–Related Loci Found with p , 5 3 10
 7 and a Sample
Size of 3,000 under a Recessive Disease Model
GRRs are chosen such that the population prevalence is equivalent to
GRRs under a multiplicative model of GRR ¼ 1.2, 1.5, 2. Rows are
(from top to bottom) GRR ¼ 1.2, 1.5, 2; columns are (from left to
right) bS ¼ 0.1, 1, 3.
Found at doi:10.1371/journal.pgen.0040033.sg004 (1.8 MB TIF).
Figure S5. Simulations Showing Frequencies of Disease-
Susceptibility–Related Loci Found with p , 5 3 10
 7 and a Sample
Size of 1,000 under a Dominant Disease Model
GRRs are chosen such that the population prevalence is equivalent to
GRRs under a multiplicative model of GRR ¼ 1.2, 1.5, 2. Rows are
(from top to bottom) GRR ¼ 1.2, 1.5, 2; columns are (from left to
right) bS ¼ 0.1, 1, 3.
Found at doi:10.1371/journal.pgen.0040033.sg005 (2.7 MB TIF).
Figure S6. Simulations Showing Frequencies of Disease-
Susceptibility–Related Loci Found with p , 5 3 10
 7 and a Sample
Size of 3,000 under a Dominant Disease Model
GRRs are chosen such that the population prevalence is equivalent to
GRRs under a multiplicative model of GRR ¼ 1.2, 1.5, 2. Rows are
(from top to bottom) GRR ¼ 1.2, 1.5, 2; columns are (from left to
right) bS ¼ 0.1, 1, 3.
Found at doi:10.1371/journal.pgen.0040033.sg006 (2.7 MB TIF).
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Inheritance
Power estimated by simulation to reach signiﬁcance level of p ¼ 5 3
10
 7, grouped by frequency 0.05–0.1, 0.1–0.15, ..., 0.45–0.5 for sample
sizes n¼1,000 and 3,000 (ﬁrst and second row, respectively) and GRRs
chosen to give same disease incidence as a multiplicative model with
GRR¼1.2, 1.5, 2 (ﬁrst second and third column, respectively). Circles
are for a recessive model, crosses are for dominant, both with
Affymetrix-like coverage.
Found at doi:10.1371/journal.pgen.0040033.sg007 (2.2 MB TIF).
Table S1. Genome-Wide Association Analyses and Follow-Up Studies
Used Here
Found at doi:10.1371/journal.pgen.0040033.st001 (47 KB DOC).
Text S1. Supplementary Text on Simulation of GWA Data
Found at doi:10.1371/journal.pgen.0040033.sd001 (23 KB DOC).
Text S2. Looking at Non-Multipicative Modes of Inheritance
Found at doi:10.1371/journal.pgen.0040033.sd002 (22 KB DOC).
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